Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript

Core Viewpoint - Neumora is discussing top line data from the Phase Ib signal-seeking study of NMRA-511, aimed at addressing agitation in Alzheimer's disease [2]. Group 1: Company Overview - The presentation is led by Helen Rubinstein, Vice President of Investor Relations and Communications at Neumora, who introduces the management team [2]. - Key members of Neumora's management team include Co-Founder and CEO Paul Berns, President Josh Pinto, Chief Scientific Officer Nick Brandon, and Chief Operating and Development Officer Bill Aurora [2]. Group 2: Study Focus - The focus of the discussion is on the Phase Ib study of NMRA-511, which targets agitation in patients with Alzheimer's disease [2].